Endometriosis features and dienogest tolerability in women with depression: a case-control study

Eur J Contracept Reprod Health Care. 2023 Jun;28(3):198-204. doi: 10.1080/13625187.2023.2199899. Epub 2023 May 3.

Abstract

Objective: Primary aim of this study was to investigate endometriosis characteristics of patients with psychiatric conditions or depression. The secondary aim was to study tolerability of dienogest in this context.

Methods: This observational case-control study included endometriosis data from patients visiting our clinic from 2015-2021. We collected information from patient charts and in phone interviews based on a structured survey. Patients with surgical confirmed endometriosis were included.

Results: 344 patients fulfilled the inclusion criteria: n = 255 no psychiatric disorder, n = 119 any psychiatric disorder and n = 70 depression. Patients with depression (EM-D, p=.018; p=.035) or psychiatric condition (EM-P, p=.020; p=.048) suffered more often from dyspareunia and dyschezia. EM-P patients had more often primary dysmenorrhoea with higher pain scores (p=.045). rASRM stage or localisation of lesions did not differ. EM-D and EM-P patients discontinued dienogest treatment more often related to worsening of mood (p= .001, p=.002).

Conclusion: EM-D or EM-P had a higher prevalence of pain symptoms. This could not be attributed to differences in rASRM stage or location of endometriosis lesions. Strong primary dysmenorrhoea might predispose to develop chronic pain-based psychological symptoms. Therefore, early diagnosis and treatment are relevant. Gynaecologist should be aware of the potential impact of dienogest on mood.

Trial registration: ClinicalTrials.gov NCT04816357.

Keywords: Endometriosis; depression; dyschezia; dysmenorrhoea; dyspareunia; psychiatric disorder.

Plain language summary

Women with endometriosis and psychiatric disorders especially have more dyschezia and dyspareunia, independent from rASRM stage, depth of infiltration and localisation of endometriosis lesions. Dienogest has an impact on mood especially in already prone patients.Trial registration: trial registration number: NCT04816357. https://clinicaltrials.gov/ct2/show/NCT04816357Date of registration: 22.03.2021, date of enrolment of the first subject: 25.03.2021.

Publication types

  • Observational Study

MeSH terms

  • Case-Control Studies
  • Depression / drug therapy
  • Dysmenorrhea / epidemiology
  • Endometriosis* / complications
  • Endometriosis* / diagnosis
  • Endometriosis* / drug therapy
  • Female
  • Humans
  • Nandrolone* / adverse effects
  • Pelvic Pain / etiology

Substances

  • dienogest
  • Nandrolone

Associated data

  • ClinicalTrials.gov/NCT04816357